PARP Inhibitors in Ovarian Cancer: A Review

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology Jg. 18; H. 4; S. 471 - 503
Hauptverfasser:	O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.07.2023 Springer Nature B.V
Schlagworte:	Bevacizumab - therapeutic use Biomedicine Carcinoma, Ovarian Epithelial - drug therapy Female Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Quality of Life Review Review Article Targeted cancer therapy United States > US
ISSN:	1776-2596, 1776-260X, 1776-260X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!